Gohara Kazuki, Okazaki Akihito, Takeda Yoshihiro, Iwasa Keiichi, Shibata Kazuhiko
Department of Respiratory Medicine, Koseiren Takaoka Hospital, 5-10 Eiraku-machi, Takaoka, 933-8555, Japan.
Department of Respiratory Medicine, Kaga Medical Center, Ri-36 Sakumi-machi, Kaga, 922-8522, Japan.
Respir Med Case Rep. 2021 Jul 8;33:101469. doi: 10.1016/j.rmcr.2021.101469. eCollection 2021.
Immune checkpoint inhibitors (ICIs) are clinically used for treating advanced lung cancer, and some patients have achieved complete remission (CR) with ICI therapy in clinical trials. However, reports summarizing the clinical courses of such patients are limited. We report two cases of lung adenocarcinoma in which CR was achieved with first-line pembrolizumab monotherapy, and the therapeutic effect was maintained after treatment completion. Specific patients can achieve CR, even those who do not meet the previously reported predictors of treatment response other than high programmed death-ligand 1 expression. Thus, biomarkers that can accurately predict the clinical efficacy of ICIs are warranted.
免疫检查点抑制剂（ICIs）在临床上用于治疗晚期肺癌，一些患者在临床试验中接受ICI治疗后实现了完全缓解（CR）。然而，总结此类患者临床病程的报告有限。我们报告两例肺腺癌患者，他们通过一线帕博利珠单抗单药治疗实现了CR，且在治疗完成后疗效得以维持。即使是那些除了程序性死亡配体1高表达外不符合先前报道的治疗反应预测指标的特定患者，也能够实现CR。因此，有必要找到能够准确预测ICIs临床疗效的生物标志物。
